Business Context and Reporting Period
This Form 6-K filing by InflaRx N.V. covers the period ending February 18, 2025. The Company, a foreign private issuer headquartered in Jena, Germany, reports the closing of a public equity offering.
Key Financial Metrics
The filing details a capital raise rather than operational financial results. Key metrics include:
- Gross Proceeds: Approximately $30 million from the initial offering.
- Potential Total Proceeds: Approximately $34.5 million if the underwriters' option is fully exercised.
- Offering Price: $2.00 per Ordinary Share.
- Pre-Funded Warrant Price: $1.999 per warrant (Offering price minus $0.001 exercise price).
- Shares Issued: 8,250,000 Ordinary Shares and pre-funded warrants for 6,750,000 Ordinary Shares.
- Option Shares: Underwriters granted a 30-day option to purchase up to 2,250,000 additional Ordinary Shares.
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity positions.
Material Changes
The primary material change is the increase in the Company's capital base through the issuance of new equity and pre-funded warrants. This transaction represents a significant dilution event for existing shareholders, increasing the total share count by 15 million units (shares plus warrants) initially, with potential for an additional 2.25 million shares.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, operational outlook, or management commentary regarding future performance. The transaction was executed pursuant to an effective shelf registration statement on Form F-3. The Underwriting Agreement includes customary indemnification provisions where the Company agrees to indemnify underwriters against certain liabilities under the Securities Act of 1933.
Investor Verification Checklist
- Verify the final exercise status of the 30-day option for 2,250,000 Option Shares to confirm total capital raised.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific underwriting discounts and offering expenses to determine net proceeds.
- Confirm the impact of the new share issuance on the Company's fully diluted share count and per-share ownership.
- Check subsequent filings for the use of proceeds, as this document does not specify the allocation of the $30 million raised.